Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $127
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Jayson Bedford has maintained an Outperform rating on Abbott Laboratories (NYSE:ABT) and increased the price target from $124 to $127.
January 25, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott Laboratories' stock may see a positive impact in the short term due to Raymond James' maintained Outperform rating and raised price target.
Analyst ratings and price target adjustments can influence investor sentiment and stock prices. The increase in price target by Raymond James suggests a bullish outlook on Abbott Laboratories, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100